Skip to content

EBITDA at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
TEC
Bio-TechneTECH
WAT
Waters CorporationWAT
Agilent Technologies logo
Agilent TechnologiesA
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$823.4M+2.7%
Gross profit$379.8M-2.9%
Operating income$10.2M-67.9%
Net income$14.4M-17.2%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$137.6M-26.7%
Total debt$1.7B-20.9%
Total equity$2.5B+34.6%
Total assets$6.1B+3.3%

Cash flow

See full
Operating cash flow$71.2M+9.5%
CapEx$24.2M-6.9%
Free cash flow$47.0M+20.5%

Valuation

See full
Market cap$8.71B-13.2%
Enterprise value$10.25B-14.9%
P/S2.5×-0.4×

Profitability

See full
Gross margin45.3%-3.7pp
Operating margin1.3%-5.0pp
Net margin-0.6%-10.0pp
FCF margin1.5%-3.6pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.7×-0.5×
Current ratio1.6×0.0×

Where this comes from

Calculated from Bruker’s reported figures.

$10.2Mebit+
$58.3MDepreciation Depletion & Amortization
=$68.5M

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bruker's EBITDA?
Bruker (BRKR) reported EBITDA of $68.5M in Q1 2026.
How has Bruker's EBITDA changed year-over-year?
Bruker's EBITDA decreased by 16.7% year-over-year, from $82.2M to $68.5M.
What is the long-term trend for Bruker's EBITDA?
Over 4 years (2021 to 2025), Bruker's EBITDA has grown at a -12.9% compound annual growth rate (CAGR), from $502.4M to $288.5M.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.